# Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors

> **NCT03352531** · PHASE1 · COMPLETED · sponsor: **Akesobio Australia Pty Ltd** · enrollment: 99 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **BIOLOGICAL:** AK-105

## Key facts

- **NCT ID:** NCT03352531
- **Lead sponsor:** Akesobio Australia Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-02
- **Primary completion:** 2020-11-30
- **Final completion:** 2023-10-28
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03352531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03352531, "Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03352531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*